Biotech Insider Buying: Novavax (NASDAQ:NVAX), Insys Therapeutics (NASDAQ:INSY), Durata Therapeutics (NASDAQ:DRTX), BioTime (NYSEMKT:BTX), OvaScience (NASDAQ:OVAS)

Biotech Insider Buying: Novavax, Inc. (NASDAQ:NVAX), Insys Therapeutics Inc. (NASDAQ:INSY), Durata Therapeutics Inc. (NASDAQ:DRTX), BioTime, Inc. (NYSEMKT:BTX), OvaScience Inc. (NASDAQ:OVAS)

John Trizzino, the senior vice president for commercial operations at Novavax Inc. (NASDAQ:NVAX), bought 16,500 shares of the compnay’s common stock on June 16. At $4.51 per share, Trizzino paid a total of $74,400 for the shares. Novavax, Inc. (NASDAQ:NVAX) weekly performance is 5.64%. On last trading day company shares ended up $4.68. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX) distance from 50-day simple moving average (SMA50) is 8.02%.

Insys Therapeutics Inc. (NASDAQ:INSY) Director John N. Kapoor bought 5,000 shares of Insys Therapeutics stock in a transaction dated Monday, June 16th. The stock was purchased at an average cost of $26.13 per share, with a total value of $130,650.00. Following the completion of the transaction, the director now directly owns 15,991 shares of the company’s stock, valued at approximately $417,845. Insys Therapeutics Inc. (NASDAQ:INSY) shares fell -4.71% in last trading session and ended the day on $28.30. INSY gross Margin is 87.90% and its return on assets is 56.80%.Insys Therapeutics Inc. (NASDAQ:INSY) quarterly performance is -39.06%.

Durata Therapeutics Inc. (NASDAQ:DRTX) CEO Paul R Edick purchased 3,000 shares of Durata Therapeutics stock in a transaction dated Thursday, June 12th. The shares were purchased at an average price of $ 15.23 per share, for a total transaction of $ 45,690.00. Durata Therapeutics Inc. (NASDAQ:DRTX) shares moved down -0.49% in last trading session and was closed at $16.37, while trading in range of $16.13 – $16.58. Durata Therapeutics Inc. (NASDAQ:DRTX) year to date (YTD) performance is 27.99%.

BioTime Inc. (NYSE:BTX) Director Broadwood Partners Lp bought 1,000,000 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $2,500,000.00. BioTime, Inc. (NYSEMKT:BTX) ended the last trading day at $3.26. Company weekly volatility is calculated as 7.39% and price to cash ratio as 35.64.BioTime, Inc. (NYSEMKT:BTX) showed a positive weekly performance of 7.59%.

OvaScience Inc. (NASDAQ:OVAS)’s director and Large Shareholder Richard Aldrich purchased 2,000 shares of common stock, at a Price of $8.52 per share. The transaction was effected pursuant to a Rule 10b5-1 trading plan. Mr. Aldrich holds now 14,850 shares in indirect form by Richard H. Aldrich 2005 Revocable Trust, from which Mr.  Aldrich has sole voting and investment power over the shares of record held by the trust. The Director owns another 3,996,052 shares through its various indirect holdings, plus 526,445 shares, which are owned directly by him.  Moreover, Mr. Aldrich has been acquiring shares of this $217.82 million Market Cap Company, specialized on Biotechnology & Medical Research, over the course of this year. In fact, during Q1 he snapped up 100,000, at a Price of $10.00 per share, and during Q2, he purchased, along with the reported 2,000, another 8,000 shares, at prices ranging from $ 7.29 to $ 7.59 per share. OvaScience Inc. (NASDAQ:OVAS) weekly performance is 6.59%. On last trading day company shares ended up $8.73. Analysts mean target price for the company is $16.17. OvaScience Inc. (NASDAQ:OVAS) distance from 50-day simple moving average (SMA50) is 11.57%.